医生和药剂师合作协议的有效性,用于在癌症患者化疗前对B型肝炎病毒进行普遍查
Hiroko Kato-Hayashi1, Kenji Imai2, Masayuki Ishida1
1Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
Anticancer research
|February 27, 2026
概括
基于协议的药物治疗管理系统显著改善了化疗前乙型肝炎病毒 (HBV) 检测率. 这一举措成功地预防了在接受化疗的患者中HBV的重新激活.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药物治疗 药物治疗
- 瘤科 支持性护理
背景情况:
- 化疗可以触发乙型肝炎病毒 (HBV) 在患者之前 HBV 感染的重新激活.
- 积极的查和管理对于在免疫抑制疗法期间预防HBV重新激活至关重要.
- 基于协议的药物治疗管理 (PBPM) 系统提供了一种结构化的方法来优化与药物相关的护理.
研究的目的:
- 评估PBPM系统在提高化疗前HBV查方面的有效性.
- 评估PBPM对关键乙型肝炎血清学标志物和HBVDNA测试的实施率的影响.
- 确定PBPM系统是否有助于预防化疗患者的HBV再激活.
主要方法:
- 在化疗前对HBV查测试订单 (HBsAg,HBcAb,HBsAb,HBV-DNA) 的回顾性分析.
- 测试实施率在三个时期的比较:PBPM前,PBPM后早期 (≤6个月) 和PBPM后晚期 (>6个月).
- 药剂师根据PBPM协议验证并订购了缺失的测试,使用基平方测试进行统计分析.
主要成果:
- 在整个过程中,B型肝炎表面抗原 (HBsAg) 测试的实施率保持在100%的水平.
- 抗HB核心抗体 (HBcAb) /抗HBs抗体 (HBsAb) 测试的实施率在PBPM后显著增加 (59.6%至98.0%,p<0.001).
- 在HBcAb/HBsAb阳性率或HBV-DNA实施率上没有观察到统计学上显著的差异;没有发生HBV重新激活病例.
结论:
- 引入PBPM系统显著提高了化疗前HBcAb和HBsAb检测率.
- 在接受化疗的患者中,PBPM系统是增强HBV查方案的有效策略.
- 该研究没有观察到任何HBV再激活病例,这表明该协议在降低风险方面取得了成功.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
302
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
267
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
267
Nursing Ethical Principles II
2.3K
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
2.3K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
316
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K


